Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025
Nektar Therapeutics (NASDAQ:NKTR) has scheduled an investor call and webcast for June 24, 2025, at 8:15 AM ET to present top-line data from the 16-week induction period of their Phase 2b REZOLVE-AD clinical trial. The study evaluates rezpegaldesleukin, a regulatory T-cell proliferator, for treating moderate-to-severe atopic dermatitis.
The data will be released via press release on the morning of the call, with webcast access details to be provided through the company's website. A replay will be available for at least 30 days after the event.
Nektar Therapeutics (NASDAQ:NKTR) ha programmato una conference call e webcast per gli investitori il 24 giugno 2025 alle 8:15 ET per presentare i dati principali del periodo di induzione di 16 settimane del loro studio clinico di Fase 2b REZOLVE-AD. Lo studio valuta rezpegaldesleukin, un proliferatore delle cellule T regolatorie, per il trattamento della dermatite atopica da moderata a grave.
I dati saranno diffusi tramite comunicato stampa la mattina della call, con i dettagli per accedere al webcast disponibili sul sito web dell'azienda. La registrazione sarà disponibile per almeno 30 giorni dopo l'evento.
Nektar Therapeutics (NASDAQ:NKTR) ha programado una llamada y webcast para inversores el 24 de junio de 2025 a las 8:15 AM ET para presentar los datos principales del periodo de inducción de 16 semanas de su ensayo clínico de Fase 2b REZOLVE-AD. El estudio evalúa rezpegaldesleukin, un proliferador de células T reguladoras, para el tratamiento de la dermatitis atópica de moderada a grave.
Los datos se publicarán mediante un comunicado de prensa la mañana de la llamada, y los detalles para acceder al webcast se proporcionarán a través del sitio web de la compañía. La repetición estará disponible por al menos 30 días después del evento.
Nektar Therapeutics (NASDAQ:NKTR)는 2025년 6월 24일 오전 8시 15분(동부시간)에 투자자 대상 전화회의 및 웹캐스트를 예정하고 있으며, 16주 유도 기간의 주요 데이터를 발표할 예정입니다. 이 임상시험은 중등도에서 중증 아토피 피부염 치료를 위한 조절 T세포 증식제인 rezpegaldesleukin을 평가하는 2b상 REZOLVE-AD 시험입니다.
데이터는 전화회의 당일 아침 보도자료를 통해 공개되며, 웹캐스트 접속 정보는 회사 웹사이트를 통해 제공됩니다. 이벤트 종료 후 최소 30일간 재방송을 시청할 수 있습니다.
Nektar Therapeutics (NASDAQ:NKTR) a programmé une conférence téléphonique et un webcast pour les investisseurs le 24 juin 2025 à 8h15 ET afin de présenter les données principales de la période d'induction de 16 semaines de leur essai clinique de phase 2b REZOLVE-AD. L'étude évalue rezpegaldesleukin, un proliférateur de cellules T régulatrices, pour le traitement de la dermatite atopique modérée à sévère.
Les données seront publiées par communiqué de presse le matin de l'appel, avec les détails d'accès au webcast disponibles sur le site web de la société. Un replay sera accessible pendant au moins 30 jours après l'événement.
Nektar Therapeutics (NASDAQ:NKTR) hat eine Telefonkonferenz und einen Webcast für Investoren am 24. Juni 2025 um 8:15 Uhr ET geplant, um die wichtigsten Daten aus der 16-wöchigen Induktionsphase ihrer Phase-2b-REZOLVE-AD-Studie vorzustellen. Die Studie bewertet rezpegaldesleukin, einen regulatorischen T-Zell-Proliferator, zur Behandlung von mittelschwerer bis schwerer atopischer Dermatitis.
Die Daten werden am Morgen der Telefonkonferenz per Pressemitteilung veröffentlicht, die Zugangsdaten zum Webcast werden auf der Website des Unternehmens bereitgestellt. Eine Wiederholung wird mindestens 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
The data will be provided in a morning press release and presented during the webcast. Details on how to access the live webcast of the call will be available in the morning press release and on the Nektar website at www.nektar.com. A replay of the webcast will be available for at least 30 days following the event.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in
For Investors:
Corey Davis, PhD
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-top-line-data-from-the-16-week-induction-period-in-rezolve-ad-phase-2b-study-of-rezpegaldesleukin-a-regulatory-t-cell-proliferator-in-atopic-dermatitis-on-june-24-2025-302488592.html
SOURCE Nektar Therapeutics
FAQ
When will Nektar (NKTR) announce the REZOLVE-AD Phase 2b trial results?
What is the purpose of Nektar's REZOLVE-AD Phase 2b trial?
How can investors access Nektar's REZOLVE-AD trial data presentation?
How long will the replay of Nektar's Phase 2b data presentation be available?
